Cardiovascular Health

The system, currently in early development in Japan, could minimize the need for blood tests, blood pressure cuffs, or expensive wearable devices.

The global temperature has risen by an average of 0.11° Fahrenheit per decade since 1850, or about 2 degrees in total.

Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, CACP will be moderating a session about social determinants of health and heart failure.

Community pharmacists are playing an increasing role in sexual and reproductive health services and can provide that trustworthy information to patients.

The 2024 American Heart Association and American Stroke Association stroke prevention guidelines recommend glucagon-like peptide-1 receptor agonists to reduce the risk of stroke in individuals with diabetes and high cardiovascular risk.

These therapies represent an encouraging advancement in cardiovascular care.

The sessions will include late-breaking science, clinical practice guidelines, early innovators spotlight sessions, and more.

Insomnia exhibits a dose-response relationship with AF recurrence, indicating that an increased number of insomnia symptoms is associated with heightened probability of AF recurrence.

The novel therapy demonstrated safety and efficacy in a clinical trial.

Historically, colchicine has been used primarily in the management of gout; however, in 2023, the FDA approved Lodoco, a newly marketed colchicine product, for the management of cardiovascular disease.

Higher doses of β-blockers are associated with better clinical outcomes in patient with heart failure.

Endometriosis is a systemic disease that can affect multiple parts of the body, not just the pelvis.

Cardiovascular diseases have a significant impact on brain health and function.

Current guidelines recommend a backbone of SLGT2 therapy in patients with HFpEF who have no contraindications.

AI-enabled remote cardiac monitoring offers continuous data on heart activity, allowing for the early detection of arrhythmias, optimized treatment timing, and improved sleep-related heart health management.

Research showed that children born via assisted reproductive technology were 36% more likely to develop heart defects.

The treatment aims to reduce prolonged QTc interval in patients with long QT syndrome.

Currently, Danon disease has a poor prognosis and does not have any pharmaceutical therapeutics for treatment or management.

The AHA acknowledged that complementary and alternative medicines are widely used by heart failure patients but warned that there is limited scientific evidence to support their efficacy.

Aaron Adkisson, PharmD, discusses the importance of considering factors such as age, gender, and cardiovascular comorbidities when monitoring and managing cardiotoxic risks in patients with cancer. also emphasizing patient education on recognizing early heart failure symptoms.

The use of devices like Apple watches may offer a more affordable and less burdensome modality to diagnose atrial fibrillation.

Parents of children with cancer had the highest risk of developing mental illness and cardiovascular diseases.

Edaravone and dexborneol sublingual tablets are an innovative first drug to be designed for treatment of stroke and granted this designation.

New insights into heart failure risks in Native American communities are highlighting the need to address social determinants of health.

Medication therapy management reimbursement can be a driving factor to work toward statin implementation in this patient group.

Investigators compare the impact of semaglutide for preserved ejection fraction and reduced ejection fraction, which both have different causes and responses to treatment.

Palliative care is crucial for safe and effective medication management to relieve symptoms and improve quality of life.

Joseph Saseen offers valuable insights into the implications of the added performance and quality measures for patients and health care providers.